Solid tumors
Biomarkers for Carcinoma Meningitis in Solid Tumors
... Carcinomatous meningitis (CM), also known as neoplastic meningitis or leptomeningeal metastasis, refers to the invasion of meninges protecting the brain and spinal cord by tumor cells. It should be distinguished from ...
13
Profile of nintedanib in the treatment of solid tumors: the evidence to date
... Abstract: Angiogenesis is an essential process for tumor growth and metastasis, and remains a promising therapeutic target process in cancer treatment for several cancer types. Bevaci- zumab, a monoclonal antibody that ...
11
The prognostic value of serum amyloid A in solid tumors: a meta-analysis
... Meta-analysis has shown that a high level of C-reac- tive protein (CRP), another acute-phase protein, is sig- nificantly associated with the poor prognosis of some cancers, including esophageal, colorectal and urologi- ...
10
Overview of the role of nanotechnological innovations in the detection and treatment of solid tumors
... Research and development into nanosystems applicable to cancer diagnosis, imaging, and therapy has emerged as one of the largest fields in nanomedicine. The substantial burden of cancer on the global population and the ...
25
EFFECTIVENESS OF CHEMOTHERAPY AMONG CHILDREN WITH SOLID TUMORS: A STUDY
... Solid tumors have been portrayed after syngeneic, allogeneic and autologous ...of solid tumors has ranged from ...of solid tumors reported in abundance among HCT beneficiaries ...
7
Amatuximab and novel agents targeting mesothelin for solid tumors
... moiety, while retaining the principal structure, confers CARs the opportunity to recognize any type of target and, therefore, to potentially affect any type of specific-antigen-expressing cancer. CARs demonstrate ...
17
Progress in the treatment of solid tumors with apatinib: a systematic review
... Apatinib is now acknowledged as a novel oral small-molecule TKI in China. Due to antiangiogenesis activity, it could be applied to a variety of solid tumors. Currently, several studies are in progress, and ...
11
Profile of farletuzumab and its potential in the treatment of solid tumors
... and 22 and to determine the maximum tolerated dose. Drug efficacy was assessed using Response Evaluation Criteria in Solid Tumors (RECIST) and by monitoring serum cancer antigen (CA) 125 levels and ...
8
Monoclonal antibodies and Fc fragments for treating solid tumors
... Abstract: Advances in biotechnology, better understanding of pathophysiological processes, as well as the identification of an increasing number of molecular markers have facilitated the use of monoclonal antibodies and ...
8
Multistep, effective drug distribution within solid tumors
... within tumors, we assessed the contribution of each factor in the transport equation, namely convection, diffusion, and ...in solid tumors assume systemic ...
14
FGFR3-TACC3 fusion in solid tumors: mini review
... In the recent years the field of medical oncology has witnessed unprecedented advances in the understanding of cancer biology. FGF/FGFR pathway is a thriving area of targeted drug development in a wide array of ...
15
Titin mutation associated with responsiveness to checkpoint blockades in solid tumors
... lung adenocarcinoma (18). However, our results revealed that the TP53/KRAS comutation was nonexis- tent in several tumor types, and thus it cannot be applied for identifying responders to ICB treatment in ...
11
Harnessing the potential of epigenetic therapy to target solid tumors
... (42–45). Tumors can dramatically differ in the numbers of focal, promoter CpG island gains in DNA methylation, as is evident in colorectal tumors (42, ...than tumors with basal or triple-negative ...
9
Current Progress in CAR-T Cell Therapy for Solid Tumors
... considered to improve the effect of CAR-T cell therapy [2, 27, 46, 101, 102]. Despite the lack of an ideal TSA, scientists have attempted to reduce the side effects of CAR-T cell therapies by investigating the ...
13
Prognostic value of spleen tyrosine kinase in human solid tumors
... the solid tumors; 2) assessing the association of SYK with OS and/or DFS; and 3) reporting sufficient information to estimate the hazard ratio (HR) and 95% ...
8
Prognostic significance of NANOG expression in solid tumors: a meta-analysis
... To our knowledge, this meta-analysis is the most thor- ough appraisal of the clinical studies that investigated the prognostic value of NANOG expression in human solid tumors. Thirty-three eligible studies ...
12
Towards extracellular matrix normalization for improved treatment of solid tumors
... of solid tumors, the dense and aberrant extracellular matrix (ECM) is a major contributor to the heterogeneous distribution of small molecule drugs and nano-formulations, which makes certain areas of the ...
21
New Strategies for the Treatment of Solid Tumors with CAR-T Cells
... enhance the activation of T cells [84]. Peptide WT1, presented in the context of HLA-A* 02:01 (RMF/A2) [85], is an important immunologically validated oncogenic target with limited expression in normal tissues, while ...
12
Profile of panobinostat and its potential for treatment in solid tumors: an update
... Several Phase I and Phase II studies have been performed to evaluate the pharmacokinetics, maximum tolerated dose (MTD), and the safety and tolerability of panobinostat in hematologic malignancies and solid ...
12
Telomere alterations in neurofibromatosis type 1-associated solid tumors
... solid tumors. Utilizing a telomere- specific FISH assay, we classified tumors as either ALT-positive or having long (without ALT), short, or normal telomere ...426 tumors from 256 NF1 patients ...
11